The European Commission announced Thursday that it had reserved 225 million doses of the potential Covid-19 vaccine from the German CureVac, the fourth agreement of this type found by the EU with laboratories.
Discussions with CureVac should result in an early purchase contract, the EU executive said in a statement.
The contract "would allow all EU member states to buy the vaccine"
The envisaged contract "would allow all EU member states to buy the vaccine and also to donate to low and middle income countries or to retransfer it to European countries," he said.
The initial purchase would be 225 million doses on behalf of EU member states, once the efficacy and safety of a vaccine has been demonstrated.
Fourth agreement found for the purchase of vaccines
This is the fourth agreement reached in connection with the purchase of vaccines by the Commission. Brussels has already reserved 300 million of the vaccine in preparation for the French Sanofi, and 400 million for that of the American Johnson & Johnson.
On August 14, the Commission also signed an advance purchase contract with the Swedish-British pharmaceutical group AstraZeneca for 300 million doses, with an option for 100 million additional doses.
“The European Commission is keeping its promise to provide Europeans and the world with rapid access to a safe vaccine that protects us against the coronavirus. Each round of negotiations that we conclude with the pharmaceutical industry brings us closer to victory against this virus ”, welcomed the President of the European Commission Ursula von der Leyen, quoted in the press release Thursday.
World
Coronavirus in Australia: Vaccination should be compulsory says Prime Minister
World
Coronavirus: Russia has produced first batch of vaccines, Russian Ministry of Health announces
- Vaccine
- Vaccination
- European Commission
- Covid 19
- Coronavirus
- Health
- World